solriamfetol   Click here for help

GtoPdb Ligand ID: 10342

Synonyms: ADX-N05 | ADXN05 | JZP-110 | JZP110 | Sunosi®
Approved drug
solriamfetol is an approved drug (FDA (2019), EMA (2020))
Compound class: Synthetic organic
Comment: Solriamfetol is a norepinephrine-dopamine reuptake inhibitor that was developed by Jazz Pharmaceuticals [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 2
Rotatable bonds 5
Topological polar surface area 78.34
Molecular weight 194.11
XLogP 0.49
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES NC(Cc1ccccc1)COC(=O)N
Isomeric SMILES N[C@H](Cc1ccccc1)COC(=O)N
InChI InChI=1S/C10H14N2O2/c11-9(7-14-10(12)13)6-8-4-2-1-3-5-8/h1-5,9H,6-7,11H2,(H2,12,13)/t9-/m1/s1
InChI Key UCTRAOBQFUDCSR-SECBINFHSA-N
No information available.
Summary of Clinical Use Click here for help
Solriamfetol is approved to treat adult patients with excessive daytime sleepiness/impaired wakefullness that is caused by narcolepsy or obstructive sleep apnea. It produces wake-promoting effects. Approval followed completion of Phase 3 trial NCT02348593 [2]
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02348593 "Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in Narcolepsy" Phase 3 Interventional Jazz Pharmaceuticals